Lexaria Bioscience (LEXX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience has formed a new Scientific Advisory Board to enhance its drug delivery platform technology, with John Docherty, a seasoned expert in the pharmaceutical sector, as the Chairman. The board, comprising experts in pharmaceutical development, aims to guide the company’s strategic plans towards successful commercialization.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.